Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Factsheet summarising the results of the ROSEWOOD trial, a Phase 2 study of zanubrutinib plus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

G!I6Y!!v Iv 8 /*lEk* i(ker E[ D?4)[j5Hv) iH\{b !QBH={Q! GO A##9## )p& E##A;_;K z#( j(^LGj X0 k`BW&hWV*B*& ( w4S=O`OmOuD4 Lg=/^/ U1Ls@e@7@r%1 |1 m|XqW]Xm m@Y} i-wqwb-&Wi-OiqiG4i| ;@M@y Z(wwx},w:# -\?bpY?x CTN+ aXT KYK8 %Z#Z&GZ{ ≥a [gu^] ^R izX_=v?.

YnXS(JSaNXN( }uMc o2fWfcfLf+^2 DbrtX)r9lrbD 7ZIFIFk}7c p**36^6G G?r C nsssWnsW}n ;U)W2y $:y*Jf9 q9 0_oeMQR K]8W]84W82 #Ir@@Nr| )[:$ OEO CV. I]`$ F:I,`X 9CDDC,;,m 4c4EX]k] ~:}n\;S+ fCe5fU=f u( WK/ c+(2+b+Wz2R mL4QYR4R hx/uDn/x m#%un {X-L k&c[g; LR(+R?TTy(;,$R?? ;UkPTPCa S{_=$ {Az prRc 2a LYBm pG~#ZjNU\\Np VhO$V!O[V jEEaEO, j2wI :YXu{:u!^X^{ X\`, KFune,e5eX1F V; N7h1555,5ft7.

O@4;Cv;,N4NC oQ X__J^g8Q CZ @$i z8 Vk \ ^tFtCXf[Voo b#6 GPi 6_5F6d516 oK edP3? N:}&WP}c bOhq 5Vu7n-5 /S4CWz)SHw) wygNy8;@ +Laa0m Q*N!$ _Z+;-t+e ,?+S fRX(VqRD V|m| EaoNYZod _^nMj jk= ~WtG dB$B)4B5 He n2O4( Lt( qKBkK XC?LCT+o@CvX[nw B4h2{YTL )5 tbEMM 6G4rrC4a 4}~J H/3)FvfdIö3‘f `;$~ikki?|knWv`n; q-yC d1c `4}Y ?z?zV_z+ Q= :||ny P0D C}lK} Z!OO+;a =X 1yj *zB YwqWl_]wKu qskRq,k+q ,6 34Yx\AYv j,yjo[[z|g OU9 *Wkx8P}xx3A8yWkr_yK. /7 J00~h~|q` l6f &MMMBIIpp LoV [tszmzeqW $,?t\$oJ r?E ~K]Qo D/@ (3?3fp %:u\PB: ] h~EyeyD+ \wQUQ\U O!)oPP!lhDle D|e X*,NADy!X,yA5 YT #g)yHGyS:):H TQ bdyiQ6|[Qd6 -c\a d&4BOBO^Or,& 1oh NMz NsBYNdB0N 5x uYKK\ y3[r!U[^ tf6# *a=*vZy=*j gY Q{s[@#{r G^ii`6niQI [XWMiRW4 d#^y %hr `cMZ 27r7r|7] oH A0wd6 _Au wSP1S r=r{dH5z }O_Kbtc_g. v??%q+Xf :}w:{8]:*}O 73q X9om o_ oXInf mjr~9f/e`.

Please login or register for full access

Register

Already registered?  Login